Mireille Sanders
Chief Operating Officer chez PHARMING GROUP N.V.
Fortune : 879 337 $ au 31/03/2024
Postes actifs de Mireille Sanders
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PHARMING GROUP N.V. | Chief Operating Officer | 15/12/2020 | - |
| Corporate Officer/Principal | 01/05/2019 | 15/12/2020 |
Historique de carrière de Mireille Sanders
Anciens postes connus de Mireille Sanders
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | 01/01/2016 | 01/01/2019 |
Formation de Mireille Sanders
| Technische Universiteit Eindhoven | Graduate Degree |
Statistiques
Internationale
| Pays-Bas | 3 |
| Etats-Unis | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Operating Officer | 1 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PHARMING GROUP N.V. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
- Bourse
- Insiders
- Mireille Sanders
- Expérience
